Genomic Health’s Colon Cancer Test Goes Worldwide
Genomic Health, a developer of genomics-based diagnostic tests, announced on Thursday the worldwide availability of its Oncotype DX Colon Cancer Test.
Ampyra Walks Away with FDA Approval
The U.S. Food and Drug Administration (FDA) has approved the first drug designed to improve walking in adults with multiple sclerosis.
Depomed Rallies for Another Round with Serada
After receiving guidance from U.S. regulators, pharmaceutical company Depomed has announced a late-stage trial of its drug candidate for menopausal hot flashes.
Access Pharma’s Drug Delivery Technology Is a Stealth Asset
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
Healthcare Conference Updates: AUXL, CTIC, CYTX, KERX
Below are some updates and developments from the past week.
[OneMedForum] NuVue Therapeutics’ Multi-Step Approach to Cancer Therapy
NuVue Therapeutics is commercializing a site-specific regimen of cancer therapy for soft tissue tumors.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
[OneMedForum] OrSense: Non-Invasive Blood Monitoring Solutions
Israel-based OrSense is attempting to increase patient compliance with a non-invasive continuous glucose monitor based on optical technology.
[OneMedForum] Jaleva Pharmaceuticals
One company presenting at the conference is San Diego-based Jaleva Pharmaceuticals, which has developed a resin-based delivery vehicle for topical medications.
Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.